上皮样血管内皮瘤疼痛评估标准(PAC-E)的前瞻性开发
基于POEM前瞻性国际观察研究(NCT06680401),54例晚期上皮样血管内皮瘤患者中15例(27.8%)出现肿瘤相关疼痛,13例(24%)最严重疼痛强度(WPI)>4。WPI>4与更短总生存相关(p<0.001),疼痛以伤害性为主并与胸膜受累相关,据此开发了EHE专属疼痛评估标准PAC-E,尚待更大 cohort 验证。
要点
- 晚期EHE患者中约四分之一存在中度至重度肿瘤相关疼痛(WPI>4)。
- WPI>4与更短总生存显著相关(p<0.001)。
- 疼痛以伤害性为主,胸膜受累者高剂量NSAIDs有效而阿片反应有限。
核心结论
- 中度至重度肿瘤相关疼痛影响约四分之一晚期EHE患者,并与更差生存相关。
研究设计与样本
- POEM研究为前瞻性、多中心、国际观察性研究(NCT06680401),自2021年3月起入组分子确诊EHE患者。
- 截至2025年6月共纳入54例晚期EHE患者,采用数字评定量表(NRS)评估肿瘤相关疼痛并以最严重疼痛强度(WPI)分析。
主要发现
- 54例中15例(27.8%)经历肿瘤相关疼痛,13例(24%)WPI>4。
- 疼痛以伤害性为主,7例与胸膜受累相关。
- 高剂量NSAIDs对胸膜性疼痛有效,阿片类药物反应有限。
- WPI>4者较WPI≤4者总生存更短(p<0.001)。
关键数值与推荐
- 临床相关疼痛定义为WPI>4。
- PAC-E通过整合纵向疼痛变化与镇痛药使用,基于POEM数据及针对性文献综述开发。
临床怎么用
- 对晚期EHE患者应常规采用NRS评估疼痛,关注WPI>4者并视为疾病侵袭性标志。
- 胸膜受累相关疼痛可优先考虑高剂量NSAIDs,阿片反应可能有限。
- PAC-E提供EHE专属标准化疼痛评估框架,可用于临床记录与研究。
局限性
- PAC-E尚需在更大队列中验证。
- 样本量54例,疼痛事件数较少(15例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Epithelioid hemangioendothelioma (EHE) is an ultra-rare sarcoma with heterogeneous behavior. Tumor-related pain is a clinically relevant symptom in advanced disease. We report the first prospective evaluation of pain in EHE, its incidence and prognostic significance, and the development of EHE-tailored Pain Assessment Criteria (PAC-E) framework. METHODS: From March 2021, patients with molecularly confirmed EHE were enrolled in the POEM study, a prospective, multicentric, international observational study (NCT06680401). Tumor-related pain was assessed using a numerical rating scale (NRS), with worst pain intensity (WPI) used for analysis. Clinically relevant pain was defined as WPI > 4. Pain characteristics, serosal involvement, analgesic response, and overall survival (OS) were evaluated. PAC-E were developed by integrating longitudinal pain changes and analgesic use, based on POEM data and a targeted literature review. RESULTS: Among 54 patients with advanced EHE enrolled by June 2025, 15 (27.8%) experienced tumor-related pain and 13 (24%) had WPI> 4. Pain was predominantly nociceptive and associated with pleural involvement (n = 7). High-potency NSAIDs were effective in patients with pleural pain and limited opioid response. WPI> 4 was associated with shorter OS compared with WPI≤ 4 (p < 0.001). PAC-E was derived from these observations. CONCLUSIONS: Moderate-to-severe tumor-related pain affected approximately one quarter of patients with advanced EHE and was associated with poorer survival. Its predominance as nociceptive pain and association with serosal involvement support its role as a clinically relevant marker of disease aggressiveness. PAC-E provides disease-specific criteria for standardized pain assessment, pending validation in larger cohorts.
引用
- Zambelli L, Zecca E, Tinè G, et al. Pain in epithelioid hemangioendothelioma: Development of disease-specific pain assessment criteria (PAC-E). Eur J Cancer. 2026. PMID: 42858623. doi:10.1016/j.ejca.2026.117769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。